BridgeBio Pharma, Inc. (BBIO)
NASDAQ
Closed
Aug 21, 2026
Day's Range
81.3652 wk Range
46.81Overview - BBIO - BridgeBio Pharma, Inc.
Key Statistics
Valuation
Enterprise Value
18.59B
P/E (Trailing)
‪-21.56‬
P/E (Forward)
‪532.05‬
PEG Ratio
‪4.74‬
Price / Sales (TTM)
‪22.34‬
Price / Book
‪-6.99‬
EV / EBITDA
‪-39.33‬
Profitability
Gross Margin
‪94.89%‬
Profit Margin
‪-97.02%‬
Operating Margin
‪-43.94%‬
Return on Assets
‪-25.99%‬
Return on Equity
‪34.90%‬
Ownership
Shares Outstanding
195.70M
Float
167.11M
Short % of Shares Outstanding
‪13.35%‬
Held by Insiders
‪3.93%‬
Held by Institutions
‪99.47%‬
Price stats
Beta
‪0.98‬
50-Day Avg
‪78.67‬
200-Day Avg
‪73.17‬
Dividends
Payout Ratio
‪0.00%‬
Analyst Consensus
22 analysts
Average price target
‪$ 108.43‬Shariah Compliance
Report Date: Feb 17, 2025
Screened by Zoya using the AAOIFI methodology.
Market Cap - BBIO - BridgeBio Pharma, Inc.
Peers - BBIO - BridgeBio Pharma, Inc.
Peer Comparison
Compared with companies in Biotechnology listed on NASDAQ.
- BBIONASDAQBridgeBio Pharma, Inc.15.93BMarket Cap+41.98%52-week change-21.56P/E (Trailing)‪-97.02%‬Profit Margin
- ARGXNASDAQargenx SE American Depositary Receipt65.04BMarket Cap+34.86%52-week change39.69P/E (Trailing)‪32.26%‬Profit Margin
- ALNYNASDAQAlnylam Pharmaceuticals Inc31.60BMarket Cap-87.81%52-week change41.15P/E (Trailing)‪16.12%‬Profit Margin
- BNTXNASDAQBioNTech SE29.28BMarket Cap+9.87%52-week change160.80P/E (Trailing)‪-63.63%‬Profit Margin
- ASNDNASDAQAscendis Pharma A/S16.61BMarket Cap+24.84%52-week change19.38P/E (Trailing)‪70.84%‬Profit Margin
- BMRNNASDAQBiomarin Pharmaceutical Inc.12.91BMarket Cap+12.29%52-week change180.16P/E (Trailing)‪2.14%‬Profit Margin
- ARWRNASDAQArrowhead Pharmaceuticals Inc.12.30BMarket Cap+76.22%52-week change47.10P/E (Trailing)‪-47.79%‬Profit Margin
Profile Summary - BBIO - BridgeBio Pharma, Inc.
About
BridgeBio Pharma, Inc. is a biotechnology company focused on discovering, developing, and delivering medicines for patients with genetic diseases and genetically driven cancers. The company concentrates on conditions with well-defined genetic causes, aiming to design targeted therapies that address the underlying…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Shariah compliance data provided by Zoya. Charting by TradingView.
Last updated:
